Interpreting Results

System

Aspirin Test

Up to 1/3 of patients on a
 ntiplatelet medications may
not receive the expected platelet inhibiting effect.1
Patients with inadequate response to their antiplatelet medications may be at
significantly greater risk of myocardial infarction, stent thrombosis and death.2-5
The VerifyNow Aspirin Test is a whole blood assay to aid in the detection of
platelet inhibition due to aspirin therapy.

What is Reported?
The lab report may look similar to the following:
***************************************************************************
Result Name
Result
Units
Reference
Platelet Response ASPIRIN
400
ARU
See Below (1)
(1) Test results are reported in Aspirin Reaction Units (ARU).
350 - 549 ARU therapeutic range for platelet function.
550 - 700 ARU NON- therapeutic range for platelet function.
***************************************************************************

Aspirin Reaction Units (ARU) indicate the amount of thromboxane A2mediated activation of GP IIb/IIIa receptors involved in platelet aggregation.
ARU is calculated as a function of the rate and extent of platelet aggregation.
Expected values are in the range of 350-700 ARU. The cut-off to determine if a
patient is receiving the therapeutic benefit of aspirin is 550.

N=1105 N=1013 N=940

Therapeutic Response

Post -PCI

30 d

N=1109 N=1012

6 mo

Post -PCI

30 d

ARU values less than 550 are consistent with a patient who is receiving the
therapeutic benefit of aspirin.

In patients with high on-treatment rea

pharmacodynamic responses to study
Patients with low levels of OTR after P

Pre-Surgical Screen

Improper sample collection

(platelet activation)
Hematologic related issues: Hct,
Platelet Count

700
650

PRU: P2Y12 REACTION UNITS

Conditions That May

Affect Test Results
May not report a result if patient has
been exposed to GP IIb/IIIa
inhibitors within:
48 hours of eptifibitide
10 days of abciximab

ARU: ASPIRIN REACTION UNITS

Price MJ,clinical
AHA 2010 decisions
Prior to surgery, the VerifyNow Aspirin Test can aid in guiding
whether to discontinue aspirin therapy or to remain on aspirin to improve graft
patency.6 Medical research suggests that there is patient variability in response
to aspirin.7 Values less than 550 ARU are reported if the patient is receiving the
therapeutic benefit of aspirin. After aspirin discontinuation, ARUs less than 550
indicate platelets remain inhibited by aspirin.

NON-THERAPEUTIC RANGE

600
550
500

THERAPEUTIC RANGE

450
400
350

350

300

250

200

150

100
50

POST ASPIRIN INGESTION

3985 Sorrento Valley Boulevard

San Diego, California USA 92121
Toll Free: 800.643.1640

For more details, see the VerifyNow Test package insert.

1 Dupont, AG. et al. Thromb Res 2009 May;124(1):6-13. 2 Patti, G. et
al. J Am Coll Cardiol 2008;52:1128-33. 3 Marcucci, R. et al. Circulation
2009;119(2):237-42. 4 Cuissett, T. et al. Am J Cardiol 2008 Jun
15;101(12):1700-3. 5 Price, MJ. et al. Eur Heart J 2008 Apr;29(8):992-1000.
6 Eagle, et. al. ACC/AHA 2004. Guideline Update for Coronary Artery
Bypass Graft Surgery. 7 Gum, et. al. Profile and Prevalence of Aspirin
Resistance in Patients with Cardiovascular Disease. J Am Coll Cardiol
2001;88:230-235.
2.0

ADAPT-DES: Relationship Betwe

P2Y12 PRU and Stent Thrombosi
Definite or probable stent thromb

DEFINITE/PROBABLE ST (%)

The VerifyNow Aspirin Test results should

be interpreted in conjuction with other
clinical and laboratory data available to the
clinician. Integrilin is a registered trademark
of Milennium Pharmaceuticals. Reopro is a
registered trademark of Centocor, Inc. Plavix is
a registered trademark of Sanofi-Synthelabo,
Inc.

P2Y12 PRU > 208 (n=3607)

1.8

P2Y12 PRU 208 (n=4834)

1.6

1.4
1.2
1.0
0.8

3985 Sorrento Valley Boulevard

San Diego, California USA 92121
Toll Free: 800.643.1640

0.6
0.4

www.accumetrics.com

0.2
0.0

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. 2013 Accumetrics, Inc. All Rights Reserved.

www.accumetrics.com

Number at risk

PN: 14341.D

10

01/2013

15

DAYS

20